Genetic make-up of rare gastrointestinal tract tumour decoded

September 11, 2013
Genetic make-up of rare gastrointestinal tract tumour decoded

Gastrointestinal stromal tumours (GIST) are relatively rare tumours of the gastrointestinal tract that can occur both as a harmless incidental finding and as aggressive, malignant disease. Two key genetic mutations that can lead to these tumours developing are already known, however it was believed that other, hitherto unknown genes, also had a role to play. Researchers at the MedUni Vienna have now successfully decoded not only individual genes, but also the entire genetic make-up of these tumours.

The working group led by Sebastian Schoppmann (University Department of Surgery), Berthold Streubel (University Department of Gynaecology) and Peter Birner (Clinical Institute of Pathology) used the next generation sequencing technique – a technique used to identify in genetic material – to analyse the entire genetic material ("exome") that is translated into proteins.

"One particular challenge is that these sequencing operations often flag up thousands of in every tumour analysed without it being clear which of them are of significance," says Birner. "By combining 'exome sequencing' with several other genetic high throughput investigation methods, however, we have been able to arrive at ten new biologically significant genes that are frequently mutated in gastrointestinal stromal tumours, and for the majority of these there has previously been no relevant data available relating to malignant diseases." It was found, for example, that mutations in the MAP kinase pathway, which is one of many involved in cell growth and , are much more common than previously suspected.

For three of these genes, the researchers at the MedUni Vienna have even been able to demonstrate direct clinical significance that was previously unknown. Says Birner: "Our results enable us to create completely new insights into the biology of GIST, which could in turn lead to new ."

The study has now been published in Clinical Cancer Research and is already the second paper published by this group in this top journal in the space of twelve months.

Explore further: Estimating the risk of bowel cancer

Related Stories

Estimating the risk of bowel cancer

August 19, 2013
Polyps in the mucosa of the colon are a common finding during screening colonoscopies. Some sub-groups of polyps are classed as precursors of bowel cancer. Until now, it has not been possible to precisely estimate the risk ...

Mutations in a gene that impacts immune function increase susceptibility to prostate cancer

August 29, 2013
A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine ...

Three out of every four cases of bladder cancer display mutations in the same gene

September 10, 2013
Researchers from the Spanish National Cancer Research Centre (CNIO) have discovered that more than 70% of bladder tumours display somatic mutations in the TERT gene (telomerase reverse transcriptase). The TERT gene is involved ...

Scouring the genome of adenoid cystic carcinoma

June 17, 2013
Adenoid cystic carcinoma (ACC) is a slow-growing and often fatal malignancy that can occur at multiple organ site, but is most frequently found in the salivary glands. The primary treatment is surgical removal; however, the ...

New approach in the treatment of breast cancer

August 8, 2013
Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team involving the Clinical ...

Whole genome or exome sequencing: An individual insight

June 27, 2013
Focusing on parts rather than the whole, when it comes to genome sequencing, might be extremely useful, finds research in BioMed Central's open access journal Genome Medicine. The research compares several sequencing technologies ...

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.